8-K: Phibro Animal Health Soars with Record Q4 & FY25 Results

Phibro Animal Health Corporation reports exceptional fourth-quarter and full-year fiscal 2025 results, driven by strong demand and a successful acquisition, while providing robust FY2026 guidance.

Summary

• Net sales for the fourth quarter ended June 30, 2025, increased by $105.5 million, or 39%, to $378.7 million.
• Full-year net sales for fiscal 2025 reached $1,296.2 million, an increase of $278.5 million, or 27%, compared to the prior year.
• Fourth-quarter net income rose significantly by $16.5 million to $17.2 million, with diluted EPS increasing by $0.40 to $0.42.
• Full-year net income surged by $45.8 million to $48.3 million, and diluted EPS increased by $1.13 to $1.19.
• Adjusted EBITDA for Q4 increased by 49% to $50.0 million, and for the full year, it grew by 65% to $183.7 million.
• Adjusted net income for Q4 increased by 39% to $23.2 million, and for the full year, it increased by 76% to $84.9 million.
• The Zoetis MFA portfolio acquisition on October 31, 2024, contributed $94.5 million in Q4 and $208.2 million for the full fiscal year to MFA and Other product sales.
• Fiscal year 2026 guidance projects net sales of $1.43 billion to $1.48 billion (12% growth) and Adjusted EBITDA of $225 million to $235 million (25% growth).

Sentiment

Score: 9

Explanation: The company reported exceptional financial results for both the quarter and the full fiscal year, with significant growth across all key metrics. The successful integration of a major acquisition and strong forward-looking guidance contribute to a highly positive sentiment.

Positives

• Exceptional fourth-quarter and full-year financial results across all key metrics.
• Significant growth in Animal Health segment, with MFA and Other product sales increasing 77% in Q4 and 54% for the full year.
• Successful integration and performance of the Zoetis MFA portfolio, exceeding expectations.
• Continued growth in nutritional specialty products (11% in Q4, 9% for FY) and vaccines (21% in Q4, 13% for FY).
• Positive demand increases in Mineral Nutrition (3% in Q4, 4% for FY) and Performance Products (13% in Q4, 19% for FY).
• Successful execution of 'Phibro Forward' initiatives, driving efficiencies and sustainable growth.
• Strong financial guidance for FY2026, projecting double-digit growth in net sales, net income, and Adjusted EBITDA.
• Free cash flow of $41.8 million for the twelve months ended June 30, 2025.

Negatives

• Gross margin decreased by 290 basis points in Q4 to 29.0% due to higher distribution costs, inventory write-offs, and unfavorable product mix, despite increased sales and average selling prices.
• Selling, general and administrative expenses (SG&A) increased by 11% in Q4 and 11% for the full year, reflecting investments and increased headcount.
• Interest expense, net, increased by 82% in Q4 and 87% for the full year due to higher debt levels associated with the acquisition financing and refinancing costs.
• Foreign currency losses, net, were $1.3 million in Q4 and $7.9 million for the full year, primarily due to fluctuations in the Israeli New Shekel, Brazilian Real, and Argentine Peso.

Risks

• Forward-looking statements are subject to risks and uncertainties, including with respect to any future debt and leverage levels.
• General risks and uncertainties are detailed in the company's Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Future Outlook

The company provides strong financial guidance for fiscal year 2026, projecting net sales between $1.43 billion and $1.48 billion (12% growth at midpoint), net income of $73 million to $83 million (63% growth), diluted EPS of $1.79 to $2.03 (61% growth), Adjusted EBITDA of $225 million to $235 million (25% growth), and Adjusted net income of $103 million to $110 million (25% growth). This growth is expected to be driven by continued expansion across Animal Health, Mineral Nutrition, and Performance Products businesses, with an adjusted effective income tax rate of approximately 25%.

Management Comments

• "Phibro delivered exceptional fourth-quarter and full-year results, reflecting the strength and balance of our Animal Health portfolio."
• "We achieved 27% growth in annual net sales and a 65% increase in adjusted EBITDA, driven by sustained demand across MFAs, nutritional specialties, and vaccines."
• "Our legacy Animal Health business continued to grow, while the Zoetis MFA portfolio exceeded expectations, contributing to a 54% year-over-year increase in MFA and Other product sales."
• "These results underscore the successful execution of our Phibro Forward initiatives, which are unlocking efficiencies and driving sustainable growth."
• "Higher SG&A reflects deliberate investments in scaling our operations to support our expanding global footprint and innovation pipeline."
• "Despite these investments, we grew adjusted net income by 76% for the year."
• "Looking ahead, our FY 2026 guidance reflects continued confidence in our trajectory, supported by the strength of our portfolio, disciplined execution, and momentum across all segments. We remain focused on driving sustainable growth and creating long-term value for our customers and shareholders."

Industry Context

The strong performance, particularly in the Animal Health segment, suggests robust demand within the global animal health industry. The successful integration of the Zoetis MFA portfolio indicates effective strategic acquisitions can drive significant market share and revenue growth. Continued growth in nutritional specialties and vaccines aligns with broader trends of increasing focus on animal well-being and productivity in livestock and companion animals. The company's expanding global footprint and innovation pipeline position it well within a growing and evolving market.

Legal Proceedings

• In fiscal year 2024, the company incurred a $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes.

Stakeholder Impact

• Shareholders are likely to benefit from the exceptional financial performance, strong growth trajectory, and positive future outlook, potentially leading to increased share value.
• Employees have seen an increase in headcount due to the acquisition and higher employee-related costs, indicating company expansion and investment in its workforce.
• Customers are experiencing sustained demand for the company's products, supported by an expanding global footprint and innovation pipeline, suggesting continued product availability and development.

Next Steps

• Host a webcast and conference call on Thursday, August 28, 2025, at 9:00 AM Eastern to review financial results and respond to questions.

Key Dates

Recommendation

Phibro Animal Health Corporation has demonstrated exceptional financial performance, significantly exceeding prior year results across all key metrics including net sales, net income, and Adjusted EBITDA. The successful integration of the Zoetis MFA portfolio has been a major growth driver, and the company's 'Phibro Forward' initiatives are yielding efficiencies. The robust FY2026 guidance projects continued strong growth, indicating sustained momentum and a positive outlook. Despite increased SG&A and interest expenses due to strategic investments and acquisition financing, the underlying operational strength and profitability are compelling for long-term investors.

Keywords

Animal Health, Phibro Animal Health Corporation, PAHC, SEC Filing, Financial Results, Earnings, Adjusted EBITDA, Net Sales, EPS, Zoetis Acquisition, Medicated Feed Additives, Vaccines, Nutritional Specialties, Mineral Nutrition, Performance Products, Fiscal Year 2025, Fiscal Year 2026 Guidance